Medicare coverage would reduce out-of-pocket costs for AOMs – which can currently be as high as $1,000 a month - by as much ...

Medigene has said it will cut 40% of its workforce and delay the start of clinical trials of its lead asset as it re-jigs its ...

Returning for its 15th anniversary year, World ADC London is the leading European conference uniting over 1000 ADC ...

The Swiss pharma group has agreed a $9 per share deal to acquire Poseida, valuing the company at around $1 billion, with another $500 million potentially payable to shareholders in a contingent value ...

In March, Winrevair became the first FDA-approved therapy for PAH that addresses the underlying mechanism behind the disease, ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...

The pharmaceutical industry operates under a complex regulatory landscape, balancing government oversight with self-imposed ...

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage non ...

The results of the phase 3 CAPItello-281 study showed that Truqap (capivasertib) improved radiographic progression-free ...

The report from techUK welcomes the new Labour government's recognition that "decisive change" – underpinned by digital ...

Halozyme made the €11-per-share offer earlier this month, valuing Evotec at around €2 billion ($2.1 billion), saying at the ...

Rumours that Donald Trump had chosen Martin Makary as FDA Commissioner have been confirmed, while the President-elect has ...